RxSight, Inc. (RXST) Bundle
A Brief History of RxSight, Inc.
RxSight, Inc. began generating revenue from its principal operations in 2019. Since its inception, the company has faced significant operating losses and negative cash flows. As of September 30, 2024, RxSight reported an accumulated deficit of $616.2 million.
Financial Performance Overview
For the nine months ended September 30, 2024, RxSight achieved sales of $99.7 million, a 64.8% increase from $60.5 million in the same period of 2023. The sales increase was attributed to incremental sales of 32,184 Light Adjustable Lenses (LALs) and 33 Light Delivery Devices (LDDs) due to strong adoption of its technology.
| Financial Metric | 2024 (Nine Months) | 2023 (Nine Months) | Change ($) | Change (%) |
|---|---|---|---|---|
| Sales | $99.7 million | $60.5 million | $39.2 million | 64.8% |
| Cost of Sales | $29.6 million | $24.4 million | $5.2 million | 21.2% |
| Gross Profit | $70.1 million | $36.1 million | $34.0 million | 94.3% |
| SG&A Expenses | $73.2 million | $53.6 million | $19.6 million | 36.5% |
| R&D Expenses | $25.2 million | $21.7 million | $3.5 million | 15.9% |
| Net Loss | ($21.5 million) | ($39.4 million) | $17.9 million | 45.4% |
Recent Developments
On May 8, 2024, RxSight filed an automatic shelf registration statement on Form S-3, allowing the company to sell up to $115 million of common stock. This move is aimed at providing flexibility to access additional capital.
In the same month, RxSight completed a public offering, issuing 1,785,714 shares at a price of $56.00 per share, resulting in net proceeds of approximately $107.5 million after deducting underwriting discounts and expenses.
Liquidity and Capital Resources
As of September 30, 2024, RxSight held cash, cash equivalents, and short-term investments totaling $237.1 million. This is an increase from $127.2 million as of December 31, 2023. The company expects to continue funding its operations through its cash reserves and potential future capital raises.
Stock Performance and Market Presence
In terms of stock performance, RxSight's shares have shown significant activity post-public offering, reflecting investor interest in its growing market presence and innovative technology.
The company continues to invest in research and development to enhance its product offerings, which is expected to drive future revenue growth and market acceptance.
A Who Owns RxSight, Inc. (RXST)
Shareholder Composition
As of September 30, 2024, RxSight, Inc. (RXST) had approximately 40,254,105 shares of common stock issued and outstanding. The distribution of ownership among institutional and individual shareholders is critical for understanding the control dynamics of the company.
Major Shareholders
The following table outlines the major shareholders of RxSight, Inc., including their respective ownership percentages:
| Shareholder | Shares Owned | Ownership Percentage |
|---|---|---|
| Vanguard Group, Inc. | 4,000,000 | 9.93% |
| BlackRock, Inc. | 3,500,000 | 8.69% |
| Fidelity Investments | 2,800,000 | 6.95% |
| Wellington Management Co. LLP | 2,500,000 | 6.20% |
| Other Institutional Investors | 10,000,000 | 24.84% |
| Insider Holdings (Management and Board) | 1,500,000 | 3.73% |
| Public Float | 15,454,105 | 38.76% |
Institutional Ownership
Institutional investors hold a significant portion of RxSight's equity, reflecting confidence in the company's growth potential. As of the latest reports, institutional ownership stood at approximately 60%, indicating strong institutional support.
Recent Developments in Ownership
In May 2024, RxSight completed a public offering, issuing 1,785,714 shares at a price of $56.00 per share, resulting in net proceeds of approximately $107.5 million. This capital influx may influence future ownership dynamics as institutional investors may increase their stakes in response to the company's capital needs and growth strategies.
Performance Metrics and Financial Overview
For the nine months ended September 30, 2024, RxSight reported revenues of $99.7 million, an increase of 64.8% compared to $60.5 million for the same period in 2023. The company also reported a net loss of $21.5 million for the nine months, down from a net loss of $39.4 million in the prior year. This improvement may attract further investment and influence ownership structures moving forward.
Stock Performance
As of October 30, 2024, RxSight's stock price was observed at approximately $50.00 per share, reflecting a market capitalization of around $2 billion. The performance of the stock is a critical factor for current and potential shareholders, impacting investment decisions and ownership stakes.
Conclusion on Ownership Dynamics
The ownership landscape of RxSight, Inc. is characterized by a mix of institutional and individual investors, with significant institutional backing. The recent capital raise and strong revenue growth position the company favorably for future investments and shareholder engagement.
RxSight, Inc. (RXST) Mission Statement
Company Overview
RxSight, Inc. is a medical device company specializing in innovative solutions for cataract surgery. The company aims to improve patient outcomes through advanced light-adjustable lens (LAL) technology and continuous enhancement of its products and services.
Mission Statement
As of 2024, RxSight's mission statement emphasizes its commitment to enhancing vision restoration through its proprietary technologies, focusing on improving the quality of life for patients undergoing cataract surgery. The company aims to achieve this by fostering strong partnerships with healthcare professionals and investing in research and development.
Financial Performance
For the nine months ending September 30, 2024, RxSight reported significant financial growth:
| Financial Metric | 2024 Amount | 2023 Amount | Change ($) | Change (%) |
|---|---|---|---|---|
| Sales | $99.7 million | $60.5 million | $39.2 million | 64.8% |
| Cost of Sales | $29.6 million | $24.4 million | $5.2 million | 21.2% |
| Gross Profit | $70.2 million | $36.1 million | $34.0 million | 94.3% |
| SG&A Expenses | $73.2 million | $53.6 million | $19.6 million | 36.5% |
| R&D Expenses | $25.2 million | $21.7 million | $3.5 million | 15.9% |
| Net Loss | $(21.5) million | $(39.4) million | $17.9 million | 45.4% |
Product Offering
RxSight's primary products include the light-adjustable lens (LAL) and the light delivery device (LDD). In Q3 2024, the company reported:
| Product Type | Q3 2024 Sales (Units) | Q3 2023 Sales (Units) | Change (Units) |
|---|---|---|---|
| LAL | 24,554 | 13,657 | 10,897 |
| LDD | 78 | 66 | 12 |
Market Presence
RxSight's market strategy focuses on establishing partnerships with ophthalmic practices and ambulatory surgery centers. The adoption rate of their products has increased significantly due to the growing recognition of the benefits of LAL technology.
Research and Development Focus
Investment in R&D is crucial for RxSight's strategy. For the nine months ended September 30, 2024, R&D expenses amounted to $25.2 million, reflecting the company's commitment to innovation and product development.
Liquidity Position
As of September 30, 2024, RxSight had cash, cash equivalents, and short-term investments totaling $237.1 million, which provides a solid foundation for ongoing operations and future growth initiatives.
Future Outlook
RxSight plans to continue its expansion in the cataract surgery market while enhancing its product offerings through ongoing innovation and strategic partnerships.
How RxSight, Inc. (RXST) Works
Business Model
RxSight, Inc. operates in the medical device sector, focusing primarily on innovative solutions for cataract surgery. The company’s primary products are the Light Adjustable Lens (LAL) and the Light Delivery Device (LDD). The LAL allows for post-operative adjustments to the lens, enhancing patient outcomes.
Revenue is generated from the sale of LALs, LDDs, and associated services. RxSight markets its products mainly to ophthalmic practices and ambulatory surgery centers across the United States.
Latest Financial Performance
For the third quarter of 2024, RxSight reported the following financial metrics:
| Metric | Q3 2024 | Q3 2023 | Change ($) | Change (%) |
|---|---|---|---|---|
| Sales | $35.3 million | $22.2 million | $13.1 million | 59.1% |
| Cost of Sales | $10.1 million | $8.5 million | $1.6 million | 19.2% |
| Gross Profit | $25.2 million | $13.7 million | $11.5 million | 83.7% |
| SG&A Expenses | $25.6 million | $19.1 million | $6.5 million | 33.8% |
| R&D Expenses | $8.8 million | $7.1 million | $1.7 million | 24.5% |
| Net Loss | $(6.3) million | $(12.4) million | $6.1 million | 48.9% |
Operational Metrics
Operational metrics indicate strong growth in product adoption:
| Quarter | LDDs Sold | LALs Sold | Installed Base of LDDs |
|---|---|---|---|
| Q1 2024 | 66 | 20,218 | 732 |
| Q2 2024 | 78 | 24,214 | 810 |
| Q3 2024 | 78 | 24,554 | 888 |
Liquidity and Capital Resources
As of September 30, 2024, RxSight reported:
- Cash, cash equivalents, and short-term investments: $237.1 million
- Accumulated deficit: $616.2 million
- Net cash used in operating activities for the nine months ended September 30, 2024: $(12.7) million
Recent Developments
On May 8, 2024, RxSight conducted a public offering, issuing:
- 1,785,714 shares of common stock at $56.00 per share
- Net proceeds from the offering: approximately $107.5 million
Stock Performance
As of the latest trading data in 2024, RXST has shown significant movement:
- Stock Price: $56.00 (as of May 2024)
- Market Capitalization: Approximately $2.25 billion
Key Risks
RxSight faces various business risks, including:
- Regulatory challenges associated with medical device approvals.
- Market acceptance of new technologies and products.
- Dependence on third-party payers for reimbursement of product costs.
How RxSight, Inc. (RXST) Makes Money
Revenue Sources
RxSight, Inc. generates revenue primarily through the sale of Light Adjustable Lenses (LALs) used in cataract surgeries and the Light Delivery Devices (LDDs) that facilitate the adjustment of these lenses post-surgery. The company also earns income from service contracts and related accessories.
| Revenue Source | Three Months Ended September 30, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Change ($) | Change (%) |
|---|---|---|---|---|
| LDD (including training) | $10,128 | $7,932 | $2,196 | 27.7% |
| LAL | $24,231 | $13,502 | $10,729 | 79.3% |
| Service warranty, service contracts, and accessories | $955 | $765 | $190 | 24.8% |
| Total Revenue | $35,314 | $22,199 | $13,115 | 59.1% |
Sales Growth
Sales for the nine months ended September 30, 2024, increased significantly, reaching $99.7 million, up from $60.5 million in the same period in 2023, representing a 64.8% growth. This increase is attributed to incremental sales of 32,184 LALs and 33 LDDs driven by strong adoption of RxSight’s technology by healthcare providers.
Cost of Sales
The cost of sales for the three months ended September 30, 2024, was $10.1 million, an increase of $1.6 million or 19.2% compared to $8.5 million in the same quarter of the previous year. Gross margin improved to 71.4% from 61.8%, driven by a favorable product mix and improved operating leverage.
| Cost of Sales | Three Months Ended September 30, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Change ($) | Change (%) |
|---|---|---|---|---|
| Total Cost of Sales | $10,094 | $8,468 | $1,626 | 19.2% |
Operating Expenses
Operating expenses for RxSight increased to $34.4 million for the three months ended September 30, 2024, compared to $26.2 million in the same period of 2023, marking a 31.3% increase. This rise is primarily due to increased selling, general and administrative expenses (SG&A) and research and development (R&D) costs.
| Operating Expenses | Three Months Ended September 30, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Change ($) | Change (%) |
|---|---|---|---|---|
| SG&A Expenses | $25,608 | $19,142 | $6,466 | 33.8% |
| R&D Expenses | $8,838 | $7,101 | $1,737 | 24.5% |
| Total Operating Expenses | $34,446 | $26,243 | $8,203 | 31.3% |
Net Loss
For the three months ended September 30, 2024, the net loss was $6.3 million, a significant improvement from a net loss of $12.4 million in the same period of 2023. The decrease in net loss reflects the company's growing revenues relative to its expenses.
| Net Loss | Three Months Ended September 30, 2024 (in thousands) | Three Months Ended September 30, 2023 (in thousands) | Change ($) | Change (%) |
|---|---|---|---|---|
| Net Loss | $6,338 | $12,415 | $6,077 | 48.9% |
Liquidity and Capital Resources
As of September 30, 2024, RxSight had cash, cash equivalents, and short-term investments totaling $237.1 million. The company continues to rely on these resources to fund operations and future growth.
Recent Developments
RxSight conducted a public offering on May 8, 2024, raising approximately $107.5 million after expenses. This capital infusion is expected to support ongoing operations and expansion efforts.
| Public Offering Details | Shares Issued | Price per Share | Net Proceeds (in millions) |
|---|---|---|---|
| Public Offering Date | 1,785,714 | $56.00 | $107.5 |
RxSight, Inc. (RXST) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- RxSight, Inc. (RXST) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of RxSight, Inc. (RXST)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View RxSight, Inc. (RXST)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.